Agilent Technologies (A) Given New $85.00 Price Target at Deutsche Bank

Agilent Technologies (NYSE:A) had its price target decreased by analysts at Deutsche Bank from $90.00 to $85.00 in a research report issued to clients and investors on Wednesday, BenzingaRatingsTable reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Deutsche Bank’s target price would suggest a potential upside of 22.66% from the stock’s current price.

A number of other brokerages have also recently weighed in on A. UBS Group began coverage on Agilent Technologies in a research report on Friday, March 15th. They set a “buy” rating and a $92.00 price target on the stock. Cowen increased their price target on Agilent Technologies from $80.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th. Barclays increased their price target on Agilent Technologies from $80.00 to $83.00 and gave the stock an “overweight” rating in a research report on Thursday, February 21st. JPMorgan Chase & Co. increased their price target on Agilent Technologies to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, February 21st. Finally, Robert W. Baird reissued a “buy” rating and issued a $82.00 price objective (up from $77.00) on shares of Agilent Technologies in a report on Wednesday, February 20th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Agilent Technologies currently has a consensus rating of “Buy” and an average price target of $86.58.

Shares of Agilent Technologies stock opened at $69.30 on Wednesday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.79 and a current ratio of 3.41. The company has a market cap of $21.48 billion, a PE ratio of 24.84, a P/E/G ratio of 1.88 and a beta of 1.33. Agilent Technologies has a twelve month low of $60.42 and a twelve month high of $82.27.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Tuesday, May 14th. The medical research company reported $0.71 earnings per share for the quarter, missing analysts’ consensus estimates of $0.72 by ($0.01). The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.27 billion. Agilent Technologies had a return on equity of 19.71% and a net margin of 22.25%. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.65 earnings per share. As a group, research analysts expect that Agilent Technologies will post 3.06 EPS for the current year.

In related news, CEO Michael R. Mcmullen sold 8,745 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $80.00, for a total value of $699,600.00. Following the completion of the transaction, the chief executive officer now directly owns 438,939 shares of the company’s stock, valued at approximately $35,115,120. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Paul N. Clark sold 2,823 shares of the stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $80.31, for a total value of $226,715.13. Following the transaction, the director now directly owns 88,857 shares of the company’s stock, valued at $7,136,105.67. The disclosure for this sale can be found here. Insiders sold a total of 48,583 shares of company stock valued at $3,855,924 over the last three months.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Parallel Advisors LLC boosted its stake in shares of Agilent Technologies by 3.9% during the 4th quarter. Parallel Advisors LLC now owns 4,002 shares of the medical research company’s stock worth $269,000 after acquiring an additional 149 shares in the last quarter. Fruth Investment Management boosted its stake in shares of Agilent Technologies by 0.3% during the 4th quarter. Fruth Investment Management now owns 45,351 shares of the medical research company’s stock worth $3,059,000 after acquiring an additional 150 shares in the last quarter. BOKF NA boosted its stake in shares of Agilent Technologies by 1.4% during the 4th quarter. BOKF NA now owns 11,229 shares of the medical research company’s stock worth $757,000 after acquiring an additional 158 shares in the last quarter. Sumitomo Life Insurance Co. boosted its stake in shares of Agilent Technologies by 1.3% during the 4th quarter. Sumitomo Life Insurance Co. now owns 13,394 shares of the medical research company’s stock worth $904,000 after acquiring an additional 178 shares in the last quarter. Finally, Mission Wealth Management LP boosted its stake in shares of Agilent Technologies by 2.1% during the 4th quarter. Mission Wealth Management LP now owns 8,629 shares of the medical research company’s stock worth $582,000 after acquiring an additional 179 shares in the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Featured Story: How to Trade Using Analysts Ratings

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.